- Nordic Nanovector ASA has appointed Alf Bjørseth as the new Chief Executive Officer (CEO) of the company.
- Bjørseth’s appointment follows the election of new board members, including Ludvik Sandnes, the former interim CFO & CEO, as the new chairman.
- Nordic Nanovector is focused on developing and delivering innovative therapies to address significant unmet medical needs and advance cancer care.
Introduction: Nordic Nanovector Welcomes New CEO
Nordic Nanovector ASA is pleased to announce the appointment of Alf Bjørseth as the company’s new Chief Executive Officer. This decision comes following the recent election of new board members, including the appointment of Ludvik Sandnes, the former interim CFO & CEO, as the chairman.
Alf Bjørseth Takes the Helm
The board of directors of Nordic Nanovector has chosen Alf Bjørseth to lead the company as its new CEO, effective immediately. As part of his employment agreement, Bjørseth’s remuneration includes a cash compensation, with at least half of the cash amount being converted into restricted share units (RSUs) in the company. The number of RSUs granted to Bjørseth will be determined based on the average trading price of the company’s shares over a ten-day period leading up to and including June 27, 2023.
About Nordic Nanovector
Nordic Nanovector is dedicated to developing and delivering innovative therapies to address significant unmet medical needs and advance cancer care. The company is committed to improving patient outcomes and making a meaningful impact in the field of oncology.